Principle Investigator, Associate Professor |School of Medicine, Department of Pharmacology
Prof. Yuhui Hu earned her Ph.D. degree at Max-Planck-Institute for Molecular Genetics (MPIMG), Berlin, Germany in 2006. Since 2007, she led her own research group on pharmacogenomics & chemical genetics in the same institute and moved in 2009 to the newly founded Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine (MDC), Berlin. Since August 2016, she was recruited as an independent PI by Southern University of Science and Technology, Shenzhen, China.
Her current lab at SUSTech focuses on integrating diverse systems biology approaches in transcriptomics genomics/epigenomics, proteomics, CRISPPR gene editing, as well as the cutting-edge single-cell and spatiotemporal omics tools to decipher the gene regulations in cancer precision medicine and developmental biology. Recently, the lab has being developing several new protocols for sample multiplexing and cell death quantification that are compatible with single cell sequencing. She has published around 40 papers in top-ranked journals with ~2000 citations (h-index 18 & i10-index 22) and submitted more than 8 patents. She has been core PI in the Shenzhen Key Laboratory of Gene Regulation and Systems Biology as well as committee member of several academic societies such as the division of anti-inflammatory and immunological pharmacology (DAIIP) of Chinese Pharmacological Society (CNPHARS), etc.
Dr. Yuhui Hu has a long-standing interest and experience in Functional Genomics, Chemical Biology, and Chinese Medicine (CM). She has particular interest in combining her expertise in both systems biology (genomics, metabolomics, proteomics) and CM theories for the research-driven development of new drugs that are originated from CM natural compounds.
She has for the first time established a series of high-throughput platforms, such as Connectivity Map of natural compounds and Transfected Cell Microarrays, for studying the functional mechanism of CM systematically, and in the meantime allowing for efficient assessment of therapeutic efficacies of CM-derived new drug candidates. The research achievement includes, for example, the first report on the genome-wide gene regulatory effects of Ginsenosides. She has identified a few CM compounds with potent anti-cancer and neural protection effects, and is currently applying these into targeted cancer therapy (Precision Medicine).
The research focus of her lab is mainly based on systems biology approaches, in particular, the functional genomic tools that cover the fields of transcriptome, genome/epigenome, gene editing, and proteome. On top of these research platforms, we applied chemical agents (including natural compounds and synthetic drugs) in order to decipher the molecular targets and underlying mechanism (effectiveness, resistance, and toxicity) of the compounds/drugs, and for a long-term goal, hope to facilitate the new drug development for different diseases.
- Systems Biology-based research of the function of CM-derived compounds and the underlying molecular mechanisms.
- Linking Chemical Biology to Cell biology: Compound-induced metabolic stress & epigenetic changes leading to a new type of DNA damage & repair.
- Cancer genomics & chemical genomics for early diagnosis, therapy, & prognosis.
- Pre-clinical study of CM-compounds for new drug development.
Her lab focuses on integrating diverse systems biology approaches (transcriptome, genome/epigenome, gene editing, and proteome) and chemical syntheses to decipher the molecular targets/mechanism of drug candidates, in particular, those bioactive compounds originated from Traditional Chinese Medicine (TCM). As a pioneer in this field, They carried out several projects including, but not limited to: 1) the first establishment of transcriptome-based functional network of TCM, namely MecoTCM; 2) the first report of complex and genomic regulatory effects of Ginsenosides; 3) the investigation of genome instability for risk assessment of carcinogenesis of TCM compounds; 4) the construction of genome-wide CRISPR/Cas9 gene editing systems for target identification of TCM compounds; 5) the utilization of chemical proteomics approaches for direct target identification of TCM compounds. For the compounds with newly identified bioactivity, several patents had been or are about to be submitted.
All the research platforms They established are not limited to the application on TCM compounds, but also applicable to any drug candidate and even existing drugs for further mechanistic study. For example, They have applied CRISPR systems for investigating the novel therapeutic and resistant mechanism of several anti-cancer drugs such as Sorafenib.
The research focus of my lab is mainly based on systems biology approaches, particularly, the functional genomic tools that cover the fields of transcriptome, spatial transcriptome, single-cell omics, genome/epigenome, gene editing, proteome, and metabolome. On top of these research platforms, we applied chemical agents (including natural compounds and synthetic drugs) in order to decipher the molecular targets and underlying mechanism (effectiveness, resistance, and toxicity) of the compounds/drugs, and for a long-term goal, hope to facilitate the new drug development for different diseases.
1) Systems Biology-based research of the novel functions of synthetic and natural compounds and the underlying molecular mechanisms, in particular, at the single-cell level.
2) Genomics of Cancer & Developmental Biology to decipher essential regulatory genes for early diagnosis, therapy, & prognosis.
3) Linking Chemical Biology to Cell biology: Compound-induced metabolic stress & epigenetic changes leading to uncharacterized type of cell death/DNA damage & repair.
4) Pre-clinical study of compound leads for new drug development.
Publications Read More
Lab members Read More
Welcome to the Department of Biology! Since its establishment in 2012, the Department of Biology has attracted internationally renowned professors to join as leaders and dozens of young scientists to start their independent academic career here pursuit of excellence in research and teaching. The research interests of our faculty members include diverse topics such as systems biology, plant biology, neurobiology, structural biology and molecular cell biology. The primary goals of our faculty are to address the most significant fundamental biological questions and to develop new strategies to treat various complex diseases. Such efforts will benefit from the shared inter-disciplinary collaborative spirit deeply rooted in the minds of all the faculty members working in different departments at SUSTech.
Mentoring the next generation biologists with the highest standards is another primary task of the Department of Biology. Our professors choose internationally acclaimed textbooks to teach core courses biological sciences, biotechnology and bioinformatics. Undergraduates are encouraged to join the laboratory early to get firsthand working experience in basic and/or applied biological research, which helps them to consolidate the mastering of basic techniques, to broaden their knowledge horizons and to acquire the capabilities of problem identifying, hypothesis formulating and problem solving.
Life science, one of the fastest developing natural scientific disciplines, has been the driving force behind the growth of the world economy and provides the know for the development of new technologies serving to improve the human health and welfare at large. Wit generous financial support from the Shenzhen municipal government, we are confident that the Department of Biology in SUSTech will surely grow into a top tier globally-renowned research and teaching center！
Master & PhD degree program: